Intravitreal Triamcinolone Acetonide Injection for Treatment of Refractory Diabetic Macular Edema A Systematic Review

被引:88
|
作者
Yilmaz, Taygan [1 ]
Weaver, Christopher D. [1 ]
Gallagher, Micheal J. [2 ]
Cordero-Coma, Miguel [3 ]
Cervantes-Castaneda, Rene A. [4 ]
Klisovic, Dino [5 ]
Lavaque, Alejandro J. [6 ]
Larson, Robin J. [1 ]
机构
[1] Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH 03766 USA
[2] Hermitage Med Clin, Dublin, Ireland
[3] Hosp Leon, Dept Ophthalmol, Leon, Spain
[4] CODET Vis Inst, Tijuana, Mexico
[5] Ohio State Univ, Columbus, OH 43210 USA
[6] Oftalmol Cristo Alvarez, San Miguel De Tucuman, Argentina
关键词
RANDOMIZED CLINICAL-TRIAL; RETINOPATHY; PHOTOCOAGULATION;
D O I
10.1016/j.ophtha.2009.02.002
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: To compare intravitreal triamcinolone acetonide (IVTA) injection versus no treatment or sub-Tenon triamcinolone acetonide (STTA) injection in improving visual acuity (VA) of patients with refractory diabetic macular edema (DME; unresponsive to focal laser therapy). Clinical Relevance: Diabetic macular edema is the leading cause of visual loss in diabetic retinopathy. Laser therapy has been the standard of care for patients with persistent or progressive disease. More recently, it has been suggested that IVTA injection may improve VA. Methods and Literature Reviewed: The following databases were searched: Medline (1950-September Week 2 2008), The Cochrane Library (Issue 3, 2008), and the TRIP Database (up to September 1, 2008), using no language or other limits. Randomized controlled trials were included that consisted of patients with refractory DME, those comparing IVTA injection with no treatment or STTA injection, those reporting VA outcomes, and those having a minimum follow-up of 3 months. Results: In the 4 randomized clinical trials comparing IVTA injection with placebo or no treatment, IVTA injection demonstrated greater improvement in VA at 3 months, but the benefit was no longer significant at 6 months. Those who received IVTA injection had significantly higher IOP at 3 months and at 6 months. In the 2 randomized clinical trials comparing IVTA injection with STTA injection, IVTA injection demonstrated greater improvement in VA at 3 months, but not at 6 months. Intravitreal triamcinolone acetonide injection demonstrated no difference in IOP at 3 months or at 6 months. Conclusions: Intravitreal triamcinolone acetonide injection is effective in improving VA in patients with refractory DME in the short-term, but the benefits do not seem to persist in the long-term. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2009;116:902-913 (C) 2009 by the American Academy of Ophthalmology.
引用
收藏
页码:902 / 911
页数:10
相关论文
共 50 条
  • [1] Intravitreal triamcinolone acetonide for refractory diabetic macular edema
    Feist, RM
    Mason, JO
    Emond, TL
    White, MF
    Thomley, ML
    Roberts, B
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 : U745 - U745
  • [2] Intravitreal injection of triamcinolone acetonide for diabetic macular edema
    Kuhn, F
    Barker, D
    ARCHIVES OF OPHTHALMOLOGY, 2004, 122 (07) : 1082 - 1083
  • [3] Pilot study of intravitreal injection of triamcinolone acetonide for refractory diabetic macular edema
    Park, PW
    Mavrofrides, E
    Mieler, WF
    Holz, ER
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 : U415 - U415
  • [4] Intravitreal triamcinolone acetonide injection as primary treatment for diabetic macular edema
    Özkiris, A
    Evereklioglu, C
    Erkiliç, K
    Tamçelik, N
    Mirza, E
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2004, 14 (06) : 543 - 549
  • [5] Intravitreal triamcinolone acetonide for refractory diabetic macular edema.
    Martidis, A
    Rogers, AH
    Greenberg, PB
    Ip, MS
    Duker, JS
    Reichel, E
    Baumal, CR
    Puliafito, CA
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2001, 42 (04) : S741 - S741
  • [6] Intravitreal injection of triamcinolone acetonide for the treatment of macular edema
    Ladjimi, A
    Zeghidi, H
    Ben Yahia, S
    Zaouali, S
    Jenzri, S
    Messaoud, R
    Attia, S
    Khairallah, M
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2005, 28 (07): : 749 - 757
  • [7] Intravitreal triamcinolone acetonide for the treatment of diabetic macular edema refractory to laser photocoagulation
    Cruz-Villegas, V
    Scott, IU
    Flynn, HW
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 : U415 - U415
  • [8] Intravitreal triamcinolone acetonide for the treatment of diabetic macular edema refractory to laser photocoagulation
    Caretti, L
    Rapizzi, E
    Cian, R
    Avarello, A
    Sato, G
    Galan, A
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 : U371 - U371
  • [9] Intravitreal triamcinolone acetonide for diabetic macular edema
    Chieh, JJ
    Roth, DB
    Liu, M
    Belmont, J
    Nelson, M
    Regillo, C
    Martidis, A
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2005, 25 (07): : 828 - 834
  • [10] The effect of posterior subtenon injection of triamcinolone acetonide for diabetic macular edema refractory to intravitreal bevacizumab injection
    Geun, Joe Soo
    Moon, Haein
    Chae, J. B.
    ACTA OPHTHALMOLOGICA, 2013, 91